Otsuka -Therapeutic Portfolios | Respiratory | Company & Drug | Global | 2024
- The document complements our standalone (detailed) company profile (which emphasis on clinical aspects more) by adding the business facet covering overall strategy, Geographical focus, Therapy area evolution within the portfolio, SWOT analysis- and how the company’s business has evolved in the last couple of years.
- The document gives a bird eyes view about the expected sales performance of the company covering the top-performing brands and therapy area focus based on their adopted business strategy. And how the company is fairing compared to its peers and what ranking changes are expected by the end of the forecast period.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Geographic Focus: China – COPD – China In-Depth (China)
COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a…
Report
Chronic Obstructive Pulmonary Disease – Access & Reimbursement – Access & Reimbursement – Chronic Obstructive Pulmonary Disease (US)
The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease | US/EU
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, LABA/LAMA/ICSs, and, most recently, the…
